SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is gaining significant attention as bullish investors react to the CEO's recent remarks hinting at "curative outcomes" for its lead AML immunotherapy, GPS, fueling high conviction about its potential and sparking discussions of a substantial short squeeze.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending due to renewed short squeeze speculation and anticipation surrounding upcoming earnings, with community discussion highlighting favorable technical chart patterns and the company's robust cash position amid its ongoing business transformation.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is trending as escalating Middle East tensions, including the Strait of Hormuz disruption and production cuts, initially sent oil prices soaring. However, immediate market conversation has shifted to the G7 and IEA's reported announcement of a massive strategic oil reserve release, prompting debate on whether the rally will continue or if a sharp downturn is imminent.

AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The firm focuses on modern biomedical and drug development to provide transformational medicines for patients suffering from infectious diseases. The company was founded by Eric Easom, George Harrison Talbot, Joseph S. Zakrzewski and Michael R.K. Alley and is headquartered in Menlo Park, CA.

AN2 Therapeutics Inc

AN2 Therapeutics is gaining attention following updates indicating clinical improvements for its epetraborole program and plans to discuss re-initiating a Phase 3 study, reversing a prior setback that caused a significant drop. This, combined with new strategic collaborations, financing, and recent insider buying, has sparked a community discussion between optimistic bulls targeting substantial gains and cautious observers anticipating further volatility.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health Inc. is trending after resolving its legal dispute with Novo Nordisk and announcing a partnership to offer FDA-approved GLP-1 weight-loss medications on its platform. This development has largely eliminated the previous bear thesis, fueling significant short-squeeze speculation and community discussion about the company's long-term potential as a digital health and wellness platform.

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is experiencing a significant surge with high volume, fueled by aggressive short covering and institutional buying, propelling it past a key resistance level. The community is actively debating a potential short squeeze and anticipating international approvals for its pioneering TIL therapy, believing the stock is fundamentally undervalued.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is trending as it staged a notable rebound from an early dip driven by escalating Middle East tensions and oil price spikes, surprising many bears who had anticipated a market collapse amid reports of oil tankers transiting the Strait of Hormuz and discussions of G7 reserve releases.

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.

Relmada Therapeutics Inc

Relmada Therapeutics is trending following positive 12-month Phase 2 trial data for its bladder cancer candidate, NDV-01, which reported a durable 76% complete response rate and reinforced plans for Phase 3 trials. The company's recently announced $160 million private placement to fund further development is also a key talking point, with the community actively discussing the drug's potential and the financing's implications for its future trajectory.

ProShares Trust - ProShares UltraShort Bloomberg Crude Oil -2x Shares

ProShares UltraShort Bloomberg Crude Oil

ProShares UltraShort Bloomberg Crude Oil ($SCO) is a hot topic as the community actively positions for a significant downturn in crude prices. Many anticipate a reversal from recent highs, believing the surge linked to geopolitical concerns and supply worries may be overextended, with discussions focused on potential reserve releases.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals is trending amid multiple analyst price target raises, with JPMorgan and Citigroup highlighting the untapped value of its Niktimvo IPF program and strong Revuforj launch performance. The community is actively discussing the stock's compelling undervaluation against peers, the competitive landscape with Kura Oncology, and significant speculation about a potential acquisition, especially with forthcoming ASH data readouts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

China's Rare Earth Dominance and the Strategic Failure of the West

China's Rare Earth Dominance and the Strategic Failure of the West China's Rare Earth Dominance and the Strategic Failure of the West PR Newswire NEW YORK, March 3, 2026 OilPrice.com Market...

VALE S.A. (VALE) Stock Drops Despite Market Gains: Important Facts to Note

In the latest trading session, VALE S.A. (VALE) closed at $16.99, marking a -1.11% move from the previous day.

Barclays Forecasts Strong Price Appreciation for Vale (NYSE:VALE) Stock

Barclays boosted their target price on Vale from $15.50 to $16.50 and gave the stock an "overweight" rating in a report on Monday...

Here's Why VALE S.A. (VALE) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Vale vs. Cleveland-Cliffs: Which Stock is a Better Buy Now?

VALE's strong output, cost cuts and rising earnings estimates stand out against CLF's losses and auto exposure. Which is the better bet?

VALE S.A. (VALE) Is a Trending Stock: Facts to Know Before Betting on It

Zacks.com users have recently been watching VALE (VALE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

VALE S.A. (VALE) is a Top-Ranked Growth Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Verus Capital Partners LLC Raises Holdings in Vale S.A. $VALE

Verus Capital Partners LLC increased its position in shares of Vale S.A. (NYSE:VALE - Free Report) by 117.0% during the 3rd quarter, according to the company in its most recent disclosure with the...

Vale S.A. $VALE Shares Sold by Journey Advisory Group LLC

Journey Advisory Group LLC cut its stake in Vale S.A. (NYSE:VALE - Free Report) by 27.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange...

Monaco Asset Management SAM Makes New Investment in Vale S.A. $VALE

Monaco Asset Management SAM acquired a new stake in shares of Vale S.A. (NYSE:VALE - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities...

Vale SA engages in the production and exportation of iron ore, pellets, manganese, and iron alloys. It operates through the following segments: Iron Solutions, Energy Transition Materials and Others. The Iron Solutions segment includes the production and extraction of iron ore, iron ore pellets, manganese, other ferrous products, and logistic services. The Energy Transition Materials segment involves the production and extraction of nickel and its by-products. Others includes the revenues and cost of other products, services, research and development, investments in joint ventures and associates of other business. The company was founded on June 1, 1942 and is headquartered in Rio de Janeiro, Brazil.

VALE
Vale S.A.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest VALE News

VALEVale S.A.